For the second straight week, there’s a new psoriatic arthritis drug on the block.
BMS forms new I-O deal with Ono, Eisai's Lenvima wins NICE nod in kidney cancer, Sanofi tries to dig out of Philippines Dengvaxia fallout.
Three major regulatory bodies – FDA, EMA and Health Canada – changed their guidelines to drug naming. How could these changes impact drug launch timelines?
As Novartis preps for its upcoming CEO transition, so too will it have to find a new leader in oncology.
With just-arrived competition in mantle cell lymphoma, J&J’s Imbruvica has snagged reimbursement backing in an important new market.
Bristol-Myers has entered the FDA fast lane with its Opdivo-plus-Yervoy combo, driving toward a new use in certain kidney cancer patients.
Pfizer now has a second FDA-approved biosimilar version of Remicade. Don't expect a sales boost from Ixifi, though. Pfizer has no plans to launch it.
Investors in five Big Pharmas want the companies to review whether their compensation plans effectively reward executives who hike prices.
Teva’s layoffs and cost cuts are here—and at 14,000 jobs and $3 billion in savings, they're far larger and deeper than reports predicted.
As questions swirl over who knew what and when in the Philippines regarding Sanofi's dengue vaccine, the company took a chance Wednesday to pause and…
Eli Lilly is aiming for $23 billion in 2018 revenue, but it'll have to contend with a tough environment in diabetes and one hefty patent expiration.